CAR T cells engineered to express IL-12p40 exhibit greater expansion, persistence, and antitumor activity in xenograft and syngeneic tumor models (151), which could be attributed to an IL-23-induced STAT3 and hypoxia inducible factor (HIF) gene signature. Here, IL23A is linked to neoplasm.